European Society for Medical Oncology (ESMO) guidelines recommend that for patients with metastatic melanoma with BRAF mutations and elevated LDH, combination therapy with ipilimumab plus nivolumab is preferred over BRAF/MEK inhibitors in the first line, though other adverse prognostic factors may also be relevant. In general, the presence of the BRAF mutation, harbored by approximately half of the melanomas, may be used to guide treatment decisions in advanced melanoma.
In addition, elevated serum LDH is a prognostic factor in patients with stage IV melanoma and is linked to greater tumor burden. A subset of patients with normal LDH levels and a lower number of organ sites who were treated with targeted combination therapy with dabrafenib and trametinib experienced durable outcomes.
Learn more about the treatment of advanced-stage melanoma.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Metastatic Melanoma Treatment - Medscape - May 24, 2023.
Comments